An outstanding article from Suzanne Kamps of Adaptimmune in Cell & Gene Therapy Insights on the growing importance of the relationship between the apheresis center and cell therapy developer/provider.

“…clearly communicating our (Adaptimmune) message about our specific treatment and allowing apheresis centers the autonomy to excel in collecting a quality starting material are real priorities for me. I want to continue to advocate for apheresis centers, and to reduce the wait-time for their participation with cell-based therapies.”

Blood Centers of America is excited to be part of the advanced therapy ecosystem Suzanne Kamps describes, all the way from early-stage development through to commercial scale-out.